News

Media

Conferences

Publications

Clinical

Events

Resources

Navigating EGFR-Mutated NSCLC: Clinical Insights for Pharmacists on Personalized Care : Episode 14

Opinion

Video

June 6, 2025

Addressing Critical Gaps in the Management of NSCLC and the Importance of the Next Wave of Treatment Advances

Author(s):

Lauren Ledbetter, PharmD, BCOP

A panelist discusses how emerging research in non–small cell lung cancer (NSCLC) is focused on determining the most effective neoadjuvant/adjuvant approaches combining chemotherapy with immunotherapy, addressing tumor heterogeneity through potential combinations of targeted therapies, and investigating mechanisms of immunotherapy nonresponse to improve patient outcomes.

EP: 1.Overcoming Challenges in NSCLC Management From a Pharmacist’s Perspective

EP: 2.First-Line Focus: Molecular Testing and Guideline-Directed Therapy in EGFR-Positive NSCLC

EP: 3.Recent Clinical Trial Highlights for NSCLC Treatment

EP: 4.Integrating Clinical Trial Findings Into Everyday Pharmacy Practice

EP: 5.Barriers to Bridging Clinical Trial Data to Routine Pharmacy Practice

EP: 6.Enhancing Patient Care Through Multidisciplinary Team Collaboration in Management of NSCLC

EP: 7.Breaking New Ground: Emerging Therapies for Treatment of EGFR-Positive NSCLC

EP: 8.Balancing Treatment and Quality of Life: Adverse Events of First-Line Agents in NSCLC

EP: 9.Strategies to Minimize Toxicities, and the Pharmacist’s Role in Educating and Supporting Patients With NSCLC

EP: 10.Infusion-Related Reactions: Clinical Trials and Guideline-Driven Prophylaxis and Management Strategies for Patients Undergoing NSCLC Treatment

EP: 11.Infusion Hesitancy and the Impact of Route of Administration of NSCLC Treatment Options in Patients’ Quality of Life

EP: 12.Streamlining the Route of Administration of Monoclonal Antibody Therapies for Better Patient Outcomes in the NSCLC Population

EP: 13.Personalized Care: How Do NSCLC Treatment Modifications and Patient-Specific Factors Impact Health Outcomes?

Now Viewing

EP: 14.Addressing Critical Gaps in the Management of NSCLC and the Importance of the Next Wave of Treatment Advances

Current Research Challenges

Early-stage NSCLC:
Multiple FDA approvals for neoadjuvant/adjuvant chemoimmunotherapy; awaiting mature data to establish optimal approach
Tumor heterogeneity: Multiple targetable mutations often present; no current data on combining targeted therapies
Immunotherapy nonresponders: Research needed to understand mechanisms of nonresponse and identify additional targets
Focus on minimizing toxicity exposure when benefit cannot be guaranteed

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!